Your browser doesn't support javascript.
loading
[Recombinant factor VIII-CVP therapy for acquired factor VIII inhibitors].
Mori, Naoki; Toyokawa, Kaoru; Teramura, Masanao; Masuda, Michihiko; Motoji, Toshiko.
Afiliação
  • Mori N; Department of Hematology, Tokyo Women's Medical University, School of Medicine.
Rinsho Ketsueki ; 48(7): 581-5, 2007 Jul.
Article em Ja | MEDLINE | ID: mdl-17695309
ABSTRACT
A 78-year-old man and an 81-year-old woman without hemophilia suddenly developed giant ecchymoses and intramuscular hemorrhage. Prolonged activated partial thromboplastin time and low factor VIII activity were observed, and the patients were subsequently diagnosed as having acquired factor VIII inhibitors. The patients were infused with one dose of recombinant factor VIII, 50 to 100 U/kg body weight, followed by cyclophosphamide, 500 mg on day 1 and 200 mg/day on days 2 to 5; vincristine, 2 mg on day 1; and prednisolone, 100 mg/day on days 1 to 5 (recombinant factor VIII-CVP therapy). Both patients responded after one course of therapy. Disappearance of inhibitors was achieved after three to four courses of therapy without subsequent recurrence. Recombinant factor VIII-CVP therapy is safe and effective in the eradication of factor VIII inhibitors.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos da Coagulação Sanguínea / Fator VIII / Protocolos de Quimioterapia Combinada Antineoplásica / Transtornos Hemorrágicos Tipo de estudo: Etiology_studies Limite: Aged / Humans / Male Idioma: Ja Ano de publicação: 2007 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos da Coagulação Sanguínea / Fator VIII / Protocolos de Quimioterapia Combinada Antineoplásica / Transtornos Hemorrágicos Tipo de estudo: Etiology_studies Limite: Aged / Humans / Male Idioma: Ja Ano de publicação: 2007 Tipo de documento: Article